| Literature DB >> 31936557 |
Sudheer S Kurup1, Richard J Staples2, Richard L Lord3, Stanislav Groysman1.
Abstract
Synthesis of new chromium(II) complexes with chelating bis(alkoxide) ligand [OO]Ph (H2[OO]Ph = [1,1':4',1''-terphenyl]-2,2''-diylbis(diphenylmethanol)) and their subsequent reactivity in the context of catalytic production of carbodiimides from azides and isocyanides are described. Two different Cr(II) complexes are obtained, as a function of the crystallization solvent: mononuclear Cr[OO]Ph(THF)2 (in toluene/THF, THF = tetrahydrofuran) and dinuclear Cr2([OO]Ph)2 (in CH2Cl2/THF). The electronic structure and bonding in Cr[OO]Ph(THF)2 were probed by density functional theory calculations. Isolated Cr2([OO]Ph)2 undergoes facile reaction with 4-MeC6H4N3, 4-MeOC6H4N3, or 3,5-Me2C6H3N3 to yield diamagnetic Cr(VI) bis(imido) complexes; a structure of Cr[OO]Ph(N(4-MeC6H4))2 was confirmed by X-ray crystallography. The reaction of Cr2([OO]Ph)2 with bulkier azides N3R (MesN3, AdN3) forms paramagnetic products, formulated as Cr[OO]Ph(NR). The attempted formation of a Cr-alkylidene complex (using N2CPh2) instead forms chromium(VI) bis(diphenylmethylenehydrazido) complex Cr[OO]Ph(NNCPh2)2. Catalytic formation of carbodiimides was investigated for the azide/isocyanide mixtures containing various aryl azides and isocyanides. The formation of carbodiimides was found to depend on the nature of organoazide: whereas bulky mesitylazide led to the formation of carbodiimides with all isocyanides, no carbodiimide formation was observed for 3,5-dimethylphenylazide or 4-methylphenylazide. Treatment of Cr2([OO]Ph)2 or H2[OO]Ph with NO+ leads to the formation of [1,2-b]-dihydroindenofluorene, likely obtained via carbocation-mediated cyclization of the ligand.Entities:
Keywords: alkoxides; azides; carbodiimides
Year: 2020 PMID: 31936557 PMCID: PMC7024303 DOI: 10.3390/molecules25020273
Source DB: PubMed Journal: Molecules ISSN: 1420-3049 Impact factor: 4.411
Scheme 1Synthesis and reactivity of Cr(II) complexes in the chelating bis(alkoxide) ligand environment.
Figure 1X-ray structures of 1 (left) and 2 (right), 50% probability ellipsoids. H atoms and co-crystallized solvent molecules were omitted for clarity. Selected bond distances (Å) and angles (°) for 1: Cr O1, 1.924(6), Cr O2, 1.935(6), Cr O3, 2.156(7), Cr O4, 2.277(6), Cr --- Ph 2.49(1), O1 Cr1 O2, 173.6(2), O1 Cr1 O3, 86.7(2), O2 Cr1 O3, 90.0(3), O1 Cr1 O4, 85.9(2), O2 Cr1 O4, 88.5(2), O3 Cr1 O4, 88.1(2). Selected bond distances (Å) and angles (°) for 2: Cr1 O1, 1.788(5), Cr2 O4, 1.799(5), Cr1 O2, 1.976(5), Cr1 O3, 2.013(6), Cr2 O3, 1.981(5), Cr2 O2, 2.049(5), Cr1 --- Cr2, 2.896(2), O2 Cr1 O3, 81.2(2), O1 Cr1 O2, 150.2(3), O1 Cr1 O3, 120.1(2).
Figure 2Corresponding orbital diagrams for 1 (left) and 1 (right) at the BP86-D3/def2-SVP level of theory. Orbitals are plotted with an isosurface value of 0.05 au.
Figure 3X-ray structure of 3 (left) and 6 (right), 50% probability ellipsoids. H atoms and co-crystallized solvent molecules were omitted for clarity. Selected bond distances (Å) for 6: Cr O1 1.807(2), Cr O2 1.777(2), Cr N1 1.645(3), Cr N2 1.716(3), N1 N3 1.305(4), N2 N4 1.301(4). Selected bond angles (°): O2 Cr O1 110.0(1), N1 Cr N3 99.7(2), N1 Cr O2 110.5(1), N2 Cr O2 109.2(1), N1 Cr O1 113.1(1), Cr N1 N3 159.8(2), Cr N2 N4 131.2(2).
Figure 4Frontier orbital diagram for 6 at the BP86-D3/def2-SVP level of theory. Orbitals are plotted with an isosurface value of 0.05 au.
Figure 5X-ray structure of 7, 50% probability ellipsoids. H atoms and co-crystallized solvent molecules were omitted for clarity.
Scheme 2Proposed cyclization mechanism of H2[OO]Ph.
Scheme 3Catalytic formation of carbodiimides mediated by 2.
X-ray crystallographic details for complexes 1–3, 6, and compound 7.
| Complex | 1 | 2 | 3 | 6 | 7 |
|---|---|---|---|---|---|
| formula | C52H46CrO4 × 2.5C7H8 | 2C88H64Cr2O4 | C58H46CrN2O2 | C70H52CrN4O2 × 0.5C6H12 × C4H8O | C22H15 × CH2Cl2 |
| fw, g/mol | 1020.25 | 2578.80 | 854.97 | 1147.34 | 364.27 |
| crystal system | Triclinic | Triclinic | Monoclinic | Triclinic | Triclinic |
| space group | |||||
| 9.946 (11) | 13.9851 (4) | 17.38 (15) | 10.1831 (6) | 8.7464 (5) | |
| 14.298 (16)) | 19.4602 (6) | 13.03 (11) | 13.0107 (7) | 8.7610 (5) | |
| 19.19 (2) | 30.4287 (10) | 28.58 (19) | 23.0961 (13) | 12.4072 (7) | |
| 83.38 (3) | 81.683 (2) | 90.00 | 100.964 (3) | 76.995 (2) | |
| 82.55 (2) | 77.609 (2) | 127.4 (4) | 101.580 (3) | 78.928 (2) | |
| 82.44 (2) | 74.125 (2) | 90.00 | 99.999 (3) | 70.505 (2) | |
| 2668 (5) | 7747.2 (4) | 5142 (71) | 2870.7 (3) | 866.13 (9) | |
|
| 2 | 4 | 4 | 2 | 2 |
| 1.270 | 1.1055 | 1.104 | 1.327 | 1.397 | |
| 0.266 | 2.673 | 0.263 | 0.257 | 0.377 | |
| 100(2) | 172.99 | 100 (2) | 100 (2) | 100 (2) | |
| 49.00 | 128.14 | 47.44 | 52.96 | 55.02 | |
| 0.0981 | 0.0827 | 0.0727 | 0.0730 | 0.0388 | |
| 0.2070 | 0.1875 | 0.1512 | 0.1710 | 0.0803 | |
| GOFc (F2) | 0.973 | 0.7573 | 0.881 | 1.037 | 1.041 |
aR1 = ∑||Fo – |Fc||/∑|Fo|. b wR2 = (∑ (w(Fo2 – Fc2)2)/∑(w(Fo2)2))1/2. c GOF = (∑w(Fo2 – Fc2)2/(n – p))1/2, where n is the number of data and P is the number of parameters refined.